Literature DB >> 16048962

Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori.

Guofei Dai1, Ni Cheng, Lei Dong, Mutsumi Muramatsu, Shudong Xiao, Ming-Wei Wang, De-Xu Zhu.   

Abstract

The antibacterial activities of NE-2001 were tested against 24 clinical isolates of Helicobacter pylori and compared with those of amoxicillin, clarithromycin, metronidazole, and furazolidone. The MIC(50) and MIC(90) of this synthetic compound on the isolates were 8 and 16 mug/ml, respectively. This action was highly selective against Helicobacter pylori; there was a >4-fold difference between the concentration of NE-2001 required to inhibit the growth of Helicobacter pylori and that required to inhibit the growth of common aerobic and anaerobic bacteria. Exposure of Helicobacter pylori (ATCC43504) to NE-2001 at the MIC (4 mug/ml), or at a greater concentration, resulted in an extensive loss of viability. The phenomenon was also observed at pH levels between 3.0 and 7.0. When two clinical Helicobacter pylori strains were successively cultured at subinhibitory concentrations of NE-2001, no significant changes in the bactericidal effects were found. The morphological alterations of Helicobacter pylori cells (ATCC43504), exposed to NE-2001 at various concentrations for 6 h, were observed using transmission electron microcopy. The bacterium displayed features such as swelling, vacuole-like structures in the cytoplasm, and cell destruction following exposure to NE-2001. The efficacy of NE-2001 was maintained when evaluated in eight clinical isolates resistant to metronidazole and five isolates resistant to both metronidazole and clarithromycin (MIC ranging between 4 and 16 mug/ml). The above-described results suggest that NE-2001 may have the potential to be developed as a candidate agent for the treatment of Helicobacter pylori infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048962      PMCID: PMC1196265          DOI: 10.1128/AAC.49.8.3468-3473.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori.

Authors:  B Björkholm; M Sjölund; P G Falk; O G Berg; L Engstrand; D I Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro.

Authors:  J E Bina; R A Alm; M Uria-Nickelsen; S R Thomas; T J Trust; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 3.  Metronidazole resistance in Helicobacter pylori.

Authors:  Peter J Jenks; David I Edwards
Journal:  Int J Antimicrob Agents       Date:  2002-01       Impact factor: 5.283

Review 4.  Helicobacter pylori therapy: first-line options and rescue regimen.

Authors:  J P Gisbert; J M Pajares
Journal:  Dig Dis       Date:  2001       Impact factor: 2.404

5.  Resistance of helicobacter pylori to metronidazole, tetracycline and amoxycillin.

Authors:  H Wu; X D Shi; H T Wang; J X Liu
Journal:  J Antimicrob Chemother       Date:  2000-07       Impact factor: 5.790

Review 6.  Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report.

Authors:  P Malfertheiner; F Mégraud; C O'Morain; A P S Hungin; R Jones; A Axon; D Y Graham; G Tytgat
Journal:  Aliment Pharmacol Ther       Date:  2002-02       Impact factor: 8.171

7.  Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance.

Authors:  D H Kwon; M Lee; J J Kim; J G Kim; F A El-Zaatari; M S Osato; D Y Graham
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

8.  Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States.

Authors:  M S Osato; R Reddy; S G Reddy; R L Penland; H M Malaty; D Y Graham
Journal:  Arch Intern Med       Date:  2001-05-14

9.  Pathogen DNA as target for host-generated oxidative stress: role for repair of bacterial DNA damage in Helicobacter pylori colonization.

Authors:  Eyleen J O'Rourke; Catherine Chevalier; A Viviana Pinto; Jean Michel Thiberge; Luis Ielpi; Agnès Labigne; J Pablo Radicella
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-24       Impact factor: 11.205

10.  A specific anti-Helicobacter pylori agent NE2001: synthesis and its effect on the growth of H. pylori.

Authors:  Ni Cheng; Jian-Shu Xie; Min-Yue Zhang; Chang Shu; De-Xu Zhu
Journal:  Bioorg Med Chem Lett       Date:  2003-08-18       Impact factor: 2.823

View more
  4 in total

1.  Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance.

Authors:  Zhaoliang Su; Huaxi Xu; Chiyu Zhang; Shihe Shao; Liangju Li; Hua Wang; Huifang Wang; Gufeng Qiu
Journal:  Croat Med J       Date:  2006-06       Impact factor: 1.351

2.  A novel defensin-like peptide from salivary glands of the hard tick, Haemaphysalis longicornis.

Authors:  Xiangyun Lu; Qiaolin Che; Yi Lv; Meijuan Wang; Zekuan Lu; Feifei Feng; Jingze Liu; Haining Yu
Journal:  Protein Sci       Date:  2010-03       Impact factor: 6.725

3.  Antibiotic resistance of Helicobacter pylori from patients in Ile-Ife, South-west, Nigeria.

Authors:  Oladiipo A Aboderin; Abdul R Abdu; Babatunde 'Wumi Odetoyin; Iruka N Okeke; Oladejo O Lawal; Dennis A Ndububa; Augustine E Agbakwuru; Adebayo Lamikanra
Journal:  Afr Health Sci       Date:  2007-09       Impact factor: 0.927

4.  Anti-Helicobacter pylori Activity of Isocoumarin Paepalantine: Morphological and Molecular Docking Analysis.

Authors:  João Paulo L Damasceno; Ricardo P Rodrigues; Rita de Cássia R Gonçalves; Rodrigo R Kitagawa
Journal:  Molecules       Date:  2017-05-12       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.